COVID-19 and diabetes mellitus: from pathophysiology to clinical management

S Lim, JH Bae, HS Kwon, MA Nauck - Nature Reviews Endocrinology, 2021 - nature.com
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Abnormal liver function tests in patients with COVID‐19: relevance and potential pathogenesis

A Bertolini, IP van De Peppel, FAJA Bodewes… - Hepatology, 2020 - journals.lww.com
Lipopolysaccharide Reverses Hepatic Stellate Cell Activation... : Hepatology Lipopolysaccharide
Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against …

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

C Axfors, AM Schmitt, P Janiaud, J Van't Hooft… - Nature …, 2021 - nature.com
Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

T Fiolet, A Guihur, ME Rebeaud, M Mulot… - Clinical microbiology …, 2021 - Elsevier
Background Hydroxychloroquine or chloroquine with or without azithromycin have been
widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro …

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

N Biran, A Ip, J Ahn, RC Go, S Wang… - The Lancet …, 2020 - thelancet.com
Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

Association between caseload surge and COVID-19 survival in 558 US hospitals, March to August 2020

SS Kadri, J Sun, A Lawandi, JR Strich… - Annals of Internal …, 2021 - acpjournals.org
Background: Several US hospitals had surges in COVID-19 caseload, but their effect on
COVID-19 survival rates remains unclear, especially independent of temporal changes in …

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19

B Singh, H Ryan, T Kredo, M Chaplin… - Cochrane Database …, 2021 - cochranelibrary.com
Background The coronavirus disease 2019 (COVID‐19) pandemic has resulted in
substantial mortality. Some specialists proposed chloroquine (CQ) and hydroxychloroquine …

Methodological quality of COVID-19 clinical research

RG Jung, P Di Santo, C Clifford… - Nature …, 2021 - nature.com
The COVID-19 pandemic began in early 2020 with major health consequences. While a
need to disseminate information to the medical community and general public was …

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

HM Dabbous, S Abd-Elsalam, MH El-Sayed… - Archives of …, 2021 - Springer
No specific antiviral drugs have been approved for the treatment of COVID-19. This study
aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter …

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

K Dhama, SK Patel, M Pathak, MI Yatoo… - Travel medicine and …, 2020 - Elsevier
Abstract Coronavirus Disease 2019 (COVID-19), emerged in early December 2019 in China
and became a pandemic situation worldwide by its rapid spread to more than 200 countries …